Amneal Targets Up to 50 Launches, But Fears Diminishing Returns

Amneal has a solid roster of generics lined up for introduction in the US this year; but challenging market dynamics are forcing the company to reassess the commercial potential of these launches.

Fifty
Amneal has up to 50 generic launches in the US scheduled for 2019 • Source: Shutterstock

Amneal expects to follow up its introduction of 42 new generics in the US last year by launching as many as 50 during the course of 2019. But with the new entrants increasingly falling into niche, specialty market segments in which substitution for the reference brand is not automatic, the US-focused company formed out of the merger of Impax and Amneal is tempering its growth expectations.

The 42 launches of drugs such as colesevelam, erythromycin, levothyroxine and phytonadione immediate-release tablets, as well as methylphenidate extended-release tablets...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin